A 64-year-old male was treated continuously with rifampin, isoniazid and streptomycin for pulmonary atypical mycobacteriosis, Mycobacterium kansasii. Five weeks after beginning the treatment, the patient suddenly developed acute renal failure. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis with moderate interstitial changes. Serum antirifampin antibody was detected, and the cessation of rifampin treatment was followed by a rapid spontaneous recovery of the patient’s renal function. This is, to our knowledge, the first case of rapidly progressive crescentic glomerulonephritis associated with rifampin treatment where circulating antirifampin antibody is demonstrated and the renal function spontaneously improved after discontinuing rifampin treatment.

Keywords:
Rapidly progressive glomerulonephritis, Rifampin, Atypical mycobacteriosis, Acute renal failure
1.
Gabow PA, Lacher JW, Neff TA: Tubulointerstitial and glomerular nephritis associated with rifampicin. JAMA 1976;23:2517–2518.
2.
Hirsch DJ, Bia FJ, Kashgarian M, Bia MJ: Rapidly progressive glomerulonephritis during antituberculous theraphy. Am J Nephrol 1983;3:7–10.
3.
Murray AN, Cassidy MJD, Templecamp C: Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis. Nephron 1987;46:373–376.
4.
Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: What should be first-line therapy. Nephron 1994;67:402–407.
5.
Weber M: Rapidly progressive glomerulonephritis: Recent advances in pathogenesis, diagnosis, and therapy. Clin Invest 1993;71:825–829.
6.
Macarron P, Garcia Díaz JE, Azofra JA, Martin de Francisco J, Gonzalez E, Fernandez G, Sampedro J: D-Penicillamine therapy associated with rapidly progressive glomerulonephritis. Nephrol Dial Transplant 1992;7:161–164.
7.
Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T, Fujinami T: A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis. Am J Kidney Dis 1992;4:411–413.
8.
Pujet JC, Homberg JC, Decroix G: Sensitivity to rifampicin: Incidence, mechanism, and prevention. BMJ 1974;ii:415–418.
9.
Qunibi WY, Godwin J, Eknoyan G: Toxic nephropathy during continuous rifampicin therapy. South Med J 1980;73:791–792.
10.
Mauri JM, Fort J, Bartolome J, Camps J, Capdevila L, Morlans M, Martin-Vega C, Piera L: Antirifampicin antibodies in acute rifampicin-associated renal failure. Nephron 1982;31:177–179.
11.
Cronin RE, Henrich WL: Toxic nephropathy; in Brenner BM, Rector FC (eds): The Kidney. Nephrotoxicity of aminoglycoside antibiotics. Philadelphia, Saunders, 1996, vol 2, pp 1681–1684.
12.
Brady HR, Brenner BM, Lieberthal W: Acute renal failure; in Brenner BM, Rector FC (eds): The Kidney. Complications of acute renal failure. Philadelphia, Saunders, 1996, vol 2, pp 1229–1231.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.